Navigation Links
ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial

Renowned cardiologists participate in controversial debate over effects of

Simvastatin vs. Ezetimibe/Simvastatin

CHICAGO, Feb. 4 /PRNewswire/ -- ReachMD, an innovative multi-channel platform for medical professionals, will air on XM Satellite Radio Channel 157 and simulcast via ReachMD Online at, a candid medical discussion on the much talked-about ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) Trial. Two of the nation's leading experts in Cardiology will share their insights over the only national broadcast network, created specifically for medical professionals.

Moderated by Dr. Matthew Sorrentino, associate professor of medicine at University of Chicago, this ReachMD Special Report will feature Dr. Steven Nissen, chairman of cardiology at the Cleveland Clinic, and Dr. Roger Blumenthal, head of preventive cardiology at Johns Hopkins University, who will for the first time openly debate among peers what this controversy means to the practicing physician and their patients.

The ENHANCE trial is a multinational, randomized, double-blind, trial that examines the effects of the highest approved dose of VYTORIN/INEGY versus the highest approved dose of simvastatin 80 mg alone in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The study was made public by Merck/Schering-Plough Pharmaceuticals.

"The debate around the clinical study on cholesterol drugs has received heavy exposure in a short amount of time," said Gary Epstein, CEO of ReachMD. "However, there hasn't been a true, peer-to-peer discussion between the leading cardiologists in this type of setting. Our Special Report offers physicians an innovative platform to hear from medical experts in an environment created specifically for medical professionals."

The ReachMD Special Report will be easily accessible to a broad medical community through multiple channels throughout the day:

-- Satellite Radio - XM Channel 157, beginning at 1:30 p.m. EST

-- Online Simulcast -, beginning at 1:30 p.m. EST

-- Downloadable Podcast - available at 6:00 a.m. EST

About ReachMD

ReachMD, headquartered in Highland Park, Illinois, is a leading provider of advanced healthcare information and education for medical professionals. ReachMD XM 157 remains committed to its mission of delivering highly relevant education, information and communication to medical professionals. The ReachMD XM channel is a new and innovative media vehicle that continues to deliver on this mission. The company's proprietary technology provides the most up-to- date healthcare information in the field through a multi-channel platform that includes satellite radio and online programs accessed through any XM radio, digital media device or PC. Through this platform, healthcare professionals receive the latest information in best practices and new advances in treatment, delivered through convenient and accessible ways. For more information, visit


Nina Velasquez

Kwittken & Company


Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
6. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
7. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
(Date:11/24/2015)... 24, 2015 --> ... Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, ... Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - ... was valued at $1.90 Billion in 2014 and is expected ... 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
Breaking Medicine News(10 mins):